Precision Medicine Diagnostics requires a test that has both high sensitivity and high specificity. Unfortunately, biomarkers that are highly specific are often low in abundance – especially in the early stages of disease.
The Ceres Nanotrap® technology, protected by 13 issued patents, increases the concentration of targeted biomarkers 10 to 1000 times. It not only captures, concentrates, and preserves the targeted biomarker, it allows detection in urine or saliva.
Ceres Nanosciences is focused on the commercialization of the Nanotrap® particle technology for sample preparation. The Nanotrap particle technology improves diagnostic testing and life science research by capturing, concentrating, and preserving low abundance analytes from biological samples. With support from the Defense Advanced Research Projects Agency, the Bill and Melinda Gates Foundation, the Defense Threat Reduction Agency, the NIH, and the Commonwealth of Virginia, Ceres is focused on incorporating this technology into a range of innovative diagnostic products.
Jan 11, 2022
Nov 9, 2021
Apr 21, 2021
Mar 30, 2021